K Number

Device Name

IMMUNICON CELLSAVE PRESERVATIVE TUBE

Manufacturer

IMMUNICON CORP.

Date Cleared

2003-08-08

(164 days)

Product Code

JKA

Regulation Number

862.1675

Intended Use

CellSave tubes are evacuated blood collection tubes that are designed to be used with standard phlebotomy supplies for venous blood collections. The tube contains 300µl of a solution that contains Na2EDTA and a cell preservative preservative preserves morphology and cell surface antigen expression of the epithelial cells and leukocytes. This tube may be used for monitoring of circulating epithelial cells (tumor cells) which may aid in the management of cancer patients. This tube may be used for monitoring CD3+/CD4+ T lymphocyte subsets which may aid in the management of patients with HIV/AIDS.

Device Description

The CellSave™ tube is an evacuated closed glass tube for collecting, transporting and processing blood. The assembly consists of a rubber stopper, a glass tube and anticoagulant. The anticoagulant contains EDTA (disodium EDTA), polyethylene glycol and a preservative reagent.

More Information

Contact

Type

Center

Panel

Date Received

Product Code

Subsequent Product Codes

Applicant Name (Manufacturer)

Device Name

Decision

Street 1

Street 2

City

State

Country Code

ZIP

Postal Code

Class Advise Committee

SSP Indicator

Third Party Reviewed

Expedited Review

Predicate Devices

K/DEN Number: Not Found

Predicate Device(s): The Becton Dickinson Vacutainer Brand Blood Collection Tube with EDTA Anticoagulant

Reference Devices

Not Found

AI/ML (Artificial Intelligence / Machine Learning)

No
The document describes a blood collection tube and its performance in preserving cells. There is no mention of AI or ML in the intended use, device description, or performance studies.

Therapeutic

No.
The device is a blood collection tube used for specimen preservation and analysis, not for treating a disease or condition.

Diagnostic

The device is a blood collection tube designed to preserve blood samples for subsequent diagnostic analysis, not to perform the diagnosis itself. Its intended use is to aid in the management of cancer and HIV/AIDS patients by preserving specific cell types for monitoring, which implies that external diagnostic tools will be used on the collected samples.

SaMD (Software as a Medical Device)

The device description clearly states it is a physical blood collection tube containing a solution and anticoagulant, which are hardware components.

IVD (In Vitro Diagnostic)

Yes, this device is an IVD (In Vitro Diagnostic).

Here's why:

Intended Use: The intended use explicitly states that the tubes are used for "monitoring of circulating epithelial cells (tumor cells) which may aid in the management of cancer patients" and "monitoring CD3+/CD4+ T lymphocyte subsets which may aid in the management of patients with HIV/AIDS." These are diagnostic purposes, providing information about a patient's health status.
Device Description: The device is a blood collection tube containing an anticoagulant and preservative. This is a common type of sample collection device used in in vitro diagnostic procedures.
Performance Studies: The document describes both nonclinical and clinical testing to evaluate the performance of the tube in preserving cells for analysis. This testing is typical for IVD devices to demonstrate their suitability for their intended diagnostic use.
Predicate Device: The predicate device listed is a "Blood Collection Tube with EDTA Anticoagulant," which is also an IVD device used for collecting blood samples for in vitro testing.

The device is designed to collect and preserve a biological sample (blood) for subsequent analysis outside of the body (in vitro) to provide information for diagnosis or management of a disease. This aligns directly with the definition of an In Vitro Diagnostic device.

PCCP (Predetermined Change Control Plan) Authorized

N/A

Overview

Intended Use / Indications for Use

The Immunicon CellSave Preservative Tube is intended for the collection and preservation of circulating epithelial cells (tumor cells) and mature human T lymphocytes (CD3+) and helper/inducer (CD3+/CD4+) T lymphocyte subsets in whole blood, to be used for enumeration and phenotyping. The device is for in vitro diagnostic use.

prescription use

Product codes

JKA

Device Description

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies

The CellSave™ Sample Tube was tested and met the applicable requirements of ISO 6710 Single Use containers for venous blood specimen collection and NCCLS Standard H1-A4 Evacuated Tubes and Additives for Blood Specimen Collection-Fourth Edition; Approved Standard.

Studies indicated that within a couple of hours epithelial cell counts decreased significantly when preserved in EDTA alone. It was also observed that separation of leukocyte sub-populations identified by cell surface antigens as measured by flow cytometry decreased over time. The use of the preservative contained within the CellSave™ tube preserved circulating epithelial cells for 72 hours and maintained the separation of the leukocyte sub-populations for 24 hours.

Recovery Study: Recovery was evaluated by spiking samples with low tumor cell numbers (0, 50, 100, and 200 cells/7.5 ml) and high tumor cell numbers (0, 100, 1000, and 10,000 cells/7.5 ml). Blood from 5 normal donors was collected into CellSave tubes and spiked with SKBR-3 cells (a breast cancer cell line). Samples were processed and stained with a nucleic acid dye, anti-CD45-APC and anti-CK-PE using the CellPrep™ Semi-Automated Processing System and analyzed using a FACSCalibur flow cytometer with beads to enable calculation of absolute counts of cells. For the low spike experiment, the regression equation was y=0.8x+4.7 and the R2 =0.98. For the high spike experiment, the regression equation was y=0.9x+6.2 and the correlation was R =0.99.

Interfering Substances Study: Blood from 5 normal donors was collected into EDTA and CellSave™ tubes and spiked with approximately 800 SKBR-3 cells. CellSave™ tubes were spiked with potential interfering substances (hemolysis 5+, lipemia 1.94-2.04% emulsified fat, icteris 7.0 mg/dl) to determine the effect on recovery and enumeration of tumor cells. Duplicate samples were processed using CellPrep™ Semi-Automated Sample Processing System and analyzed using the FACSCalibur flow cytometer. Hemolysis, lipemic and icteric whole blood samples collected into the CellSave™ tube do not interfere with the recovery and enumeration of tumor cells.

Clinical Study 1 (Metastatic Cancer Patients): A Clinical study was performed at Immunicon using blood samples obtained from five geographically dispersed sites from 102 metastatic cancer patients providing 107 blood specimens for analysis. Seventy of these specimens had sufficient blood volume for testing at approximately 24 hours and again at approximately 96 hours. Initial circulating epithelial cell (tumor cell, or CTC) counts ranged from 0 to 640 CTC per sample. Twenty-one of these specimens had an average of greater than or equal to 3 CTC at the two testing time points. The linear correlation for CTC recovery over this time period comparing 24 hours to 96 hours was an R2 equal to 1.00 with a regression equation of y=1.1x-7.1. A Wilcoxon signrank test indicated that the CTC counts obtained at 24 hours and those obtained at 96 hours were not significantly different (p > 0.90). These data demonstrate that the recovery of circulating epithelial cells from whole blood remains stable over a 72 hour time period using the CellSave™ blood collection tube.

Clinical Study 2 (CD3/CD4 Immunophenotyping): A second clinical study was performed to compare CD3/CD4 immunophenotyping over a 72 hour time period using both EDTA and CellSave™ tubes. Whole blood samples were obtained from fifty healthy volunteers and twelve patients with confirmed HIV. Results of CD3/CD4 testing on days 1, 2, and 3 resulted in Revalues during the three days of between 0.97 and 0.98 and slopes of 0.91 to 0.97.

Overall Conclusion: These studies demonstrate that the CellSave™ blood collection tube is effective in preserving T lymphocytes and epithelial cells for phenotyping and enumeration over a 72 hour time period. The numbers of CD3 and CD4 positive lymphocytes and epithelial cells are unchanged over a 72-hour period. Preservation of T lymphocytes and their antigens are also effective using different instruments for enumeration of labeled cells, which demonstrates that the CellSave™ tube is useful across multiple instruments. These studies justify the use of the CellSave tube for drawing, shipping and storing venous blood up to 72 hours for the counting and immunophenotyping of epithelial cells and leukocytes.

Key Metrics

Recovery: Low spike: R2 = 0.98 for y=0.8x+4.7. High spike: R = 0.99 for y=0.9x+6.2.
% Recovery: Low spike mean: 89.3% (50 cells), 88.2% (100 cells), 81.4% (200 cells). High spike mean: 91.3% (100 cells), 86.7% (1,000 cells), 85.7% (10,000 cells).
Interfering Substances:
CellSave™ Control: Mean % Recovery = 72%, SD = 22%.
CellSave™ Hemolysis: Mean % Recovery = 74%, SD = 6%.
CellSave™ Lipemia: Mean % Recovery = 90%, SD = 10%.
CellSave™ Icteris: Mean % Recovery = 85%, SD = 9%.
Clinical Study 1: R2 = 1.00 for y=1.1x-7.1 (CTC recovery 24 hours vs 96 hours). Wilcoxon signrank test: p > 0.90 (no significant difference in CTC counts at 24 vs 96 hours).
Clinical Study 2: CD3/CD4 testing R values (Days 1, 2, 3) between 0.97 and 0.98. Slopes between 0.91 and 0.97.

Predicate Device(s)

The Becton Dickinson Vacutainer Brand Blood Collection Tube with EDTA Anticoagulant.

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

Regulation Number and Section

§ 862.1675 Blood specimen collection device.

(a)
Identification. A blood specimen collection device is a device intended for medical purposes to collect and to handle blood specimens and to separate serum from nonserum (cellular) components prior to further testing. This generic type device may include blood collection tubes, vials, systems, serum separators, blood collection trays, or vacuum sample tubes.(b)
Classification. Class II.

Summary

KC030596

510(k) Summary

Date prepared August 5, 2003.

This 510(k) summary is being submitted in accordance with the requirements of 21 CFR 807.92 (c).

The assigned 510(k) number is K030596.

The submitter of this premarket notification is Immunicon Corporation, 3401 Masons Mill Road. Suite 100. Huntingdon Valley, PA 19006. The official correspondent is Peter J Scott. Vice President of Quality Assurance and Regulatory Affairs (215-830-0777 ext 235, fax 215-830-0751).

The subject of this summary of Safety and Effectiveness is the Immunicon CellSave™ Preservative Tube. The predicate device is the Becton Dickinson Vacutainer Brand Blood Collection Tube with EDTA Anticoagulant. The Immunicon CellSave Preservative Tube is intended for the collection and preservation of circulating epithelial cells (tumor cells) and mature human T lymphocytes (CD3+) and helper/inducer (CD3+/CD4+) T lymphocyte subsets in whole blood, to be used for enumeration and phenotyping. The device is for in vitro diagnostic use.

NONCLINICAL TESTING

PERFORMANCE

Recoverv

Recovery was evaluated by spiking samples with low tumor cell numbers (0, 50, 100, and 200 cells/7.5 ml) and high tumor cell numbers (0, 100, 1000, and 10,000 cells/7.5 ml). Blood from 5 normal donors was collected into CellSave tubes and spiked with SKBR-3 cells (a breast cancer cell line). Samples were processed and stained with a nucleic acid dye, anti-CD45-APC and anti-CK-PE using the CellPrep™ Semi-Automated Processing System and analyzed using a FACSCalibur flow cytometer with beads to enable calculation of absolute counts of cells. For the low spike experiment, the regression equation was y=0.8x+4.7 and the R2 =0.98. For the high spike experiment, the regression equation was y=0.9x+6.2 and the correlation was R =0.99.

	Low spike				High Spike
Donor	0	50	100	200	0	100	1,000	10,000
A	2	31	89	164	2	84	876	8,259
B	2	44	97	141	4	74	775	8,185
C	5	51	92	175	1	75	880	9,342
D	1	46	81	153	2	118	846	8,030
E	4	52	82	181	2	106	959	9,014
Mean	3	45	88	163	2	91	867	8,566
% Recovery		89.3%	88.2%	81.4%		91.3%	86.7%	85.7%

Interfering substances

Blood from 5 normal donors was collected into EDTA and CellSave™ tubes and spiked with approximately 800 SKBR-3 cells. CellSave™ tubes were spiked with potential interfering substances (hemolysis 5+, lipemia 1.94-2.04% emulsified fat, icteris 7.0 mg/dl) to determine the effect on recovery and enumeration of tumor cells. Duplicate samples were processed using CellPrep™ Semi-Automated Sample Processing System and analyzed using the FACSCalibur flow cytometer.

Donor	EDTA Control			CellSave™ Control
	# Cells Recovered	# Cells Spiked	% Recovery	# Cells Recovered	# Cells Spiked	% Recovery
A1	452	828	55%	388	696	56%
A2	445	828	54%	486	696	70%
B1	802	749	107%	689	696	99%
B2	711	749	95%	690	696	99%
C1	580	771	75%	289	716	40%
C2	451	771	58%	272	716	38%
D1	571	771	74%	552	716	77%
D2	642	771	83%	636	716	89%
E1	610	771	79%	526	716	73%
E2	541	771	70%	535	716	75%
Mean	581		75%	506		72%
SD	117		17%	150		22%

CellSave TM, Hemolysis			CellSave TM, Lipemia			CellSave TM, Icteris
Donor	# Cells
Recovered	# Cells
Spiked	%
Recovery	# Cells
Recovered	# Cells
Spiked	%
Recovery	# Cells
Recovered	# Cells
Spiked	%
Recovery
A1	482	696	69%	664	696	95%	638	696	92%
A2	502	696	72%	691	728	95%	612	728	84%
B1	514	696	74%	748	696	107%	678	696	97%
B2	571	696	82%	712	696	102%	679	696	98%
C1	499	716	70%	568	716	79%	561	716	78%
C2	470	716	66%	599	716	84%	514	716	72%
D1	582	716	81%	628	716	88%	651	716	91%
D2	551	716	77%	549	716	77%	589	716	82%
E1	571	716	80%	620	716	87%	554	716	77%
E2	499	716	70%	620	716	87%	584	716	82%
Mean	524		74%	640		90%	606		85%
SD	41		6%	63		10%	55		9%

Hemolysis, lipemic and icteric whole blood samples collected into the CellSave™ tube do not interfere with the recovery and enumeration of tumor cells.

CLINICAL TESTING

A Clinical study was performed at Immunicon using blood samples obtained from five geographically dispersed sites from 102 metastatic cancer patients providing 107 blood specimens for analysis. Seventy of these specimens had sufficient blood volume for testing at approximately 24 hours and again at approximately 96 hours. Initial circulating epithelial cell (tumor cell, or CTC) counts ranged from 0 to 640 CTC per sample. Twenty-one of these specimens had an average of greater than or equal to 3 CTC at the two testing time points. The linear correlation for CTC recovery over this time period comparing 24 hours to 96 hours was an R2 equal to 1.00 with a regression equation of y=1.1x-7.1. A Wilcoxon signrank test indicated that the CTC counts obtained at 24 hours and those obtained at 96 hours were not significantly different (p > 0.90). These data demonstrate that the recovery of circulating epithelial cells from whole blood remains stable over a 72 hour time period using the CellSave™ blood collection tube.

A second clinical study was performed to compare CD3/CD4 immunophenotyping over a 72 hour time period using both EDTA and CellSave™ tubes. Whole blood samples were obtained from fifty healthy volunteers and twelve patients with confirmed HIV. Results of CD3/CD4 testing on days 1, 2, and 3 resulted in Revalues during the three days of between 0.97 and 0.98 and slopes of 0.91 to 0.97.

Together, these studies demonstrate that the CellSave™ blood collection tube is effective in preserving T lymphocytes and epithelial cells for phenotyping and enumeration over a 72 hour time period. The numbers of CD3 and CD4 positive lymphocytes and epithelial cells are unchanged over a 72-hour period. Preservation of T lymphocytes and their antigens are also effective using different instruments for enumeration of labeled cells, which demonstrates that the CellSave™ tube is useful across multiple instruments.

These studies justify the use of the CellSave tube for drawing, shipping and storing venous blood up to 72 hours for the counting and immunophenotyping of epithelial cells and leukocytes.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Image /page/3/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. In the center of the circle is an abstract symbol that resembles a caduceus, a traditional symbol of medicine.

AUG - 8 2003

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Mr. Peter J. Scott Vice President of Quality Assurance and Regulatory Affairs Immunicon® Corporation 3401 Masons Mill Road - Suite 100 Huntingdon Valley, PA 19006

Re: K030596

Trade/Device Name: The Immunicon CellSave™ Preservation Tube Regulation Number: 21 CFR 862.1675 Regulation Name: Blood specimen collection device Regulatory Class: Class II Product Code: JKA Dated: June 3, 2003 Received: June 4, 2003

Dear Mr. Scott:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Steven Sutman

Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

Page of

510(k) Number (if known):	K030596
Device Name:	The Immunicon CellSave TM Preservation Tube
Indications For Use:

prescription use

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Josephine Bautista

Division Sign-Off

(Optional Format 3-10-98)

Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) K030596